Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer

<b>Background/Objectives</b>: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature an...

Descripció completa

Dades bibliogràfiques

Autors principals:	Taraneh Sadat Zavvar, Giulia Santo, Leonhard Gruber, Ariane Kronthaler, Judith Hagenbuchner, Ira Skvortsova, Inken Piro, Katja Steiger, Vladan Martinovic, Danijela Minasch, Judith Löffler-Ragg, Gianpaolo di Santo, Irene J. Virgolini, Elisabeth von Guggenberg
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2026-01-01
Col·lecció:	Pharmaceutics
Matèries:	peptide receptor radionuclide therapy cholecystokinin-2 receptor minigastrin SPECT/CT imaging first-in-human
Accés en línia:	https://www.mdpi.com/1999-4923/18/1/138
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!